Timothy Caulfield, JD, discusses the sessions he's most looking forward to at this year's Society for Pediatric Dermatology annual meeting, including his talk on overcoming misinformation in pediatric dermatology.
Timothy Caulfied, JD, professor in the Faculty of Law in the School of Public Health and research director of the Health Law Institute at the University of Alberta, discusses the sessions he's most looking forward to at this year's Society of Pediatric Dermatology (SPD) annual meeting, including his talk on overcoming misinformation in pediatric dermatology.
Transcript
What sessions are you most looking forward to checking out at SPD 2024?
You know, I'm really looking forward to talking to this community. First of all, I think this community is incredibly relevant. I think this is a hot topic for this community, for this audience. So I'm looking forward to engaging with them. And also [I'm] really interested in their thoughts about what kinds of issues in the misinformation sphere they're seeing. But the other reason I'm thrilled to have this opportunity is I think this community can make a real difference. We know that there's been an erosion in trust for institutions generally—for science and, yes, for physicians—but health care providers are still amongst the most trusted voices, especially when you're talking about that physician-patient relationship. So, yeah, [I'm] very excited to talk with this community and looking forward to the event.
What will audiences be able to take away from your presentation on misinformation in the field of pediatric dermatology?
Look, I hope it was obvious that this is a major problem. I think that the spread of health misinformation is one of the greatest challenges of our time, and I really tried to hammer that.
I don't think that's a hard sell for this community but the scope and the breadth of the problem is really tremendous. And so the presentation was a little bit a call to arms, right? You know, we need everyone to step up.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More